Condition

Adjuvant Treatment

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting1

Common interventions6

Lead sponsors shown3

Clinical trials

3 shown

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer PatientsNCT07071038 · 2025-10-17

RECRUITING

Evaluation of the Efficacy and Acceptability of a Phytotherapy Combining Devil's Claw, Blackcurrant and Meadowsweet for the Management of Aromatase Inhibitor-induced Arthralgia in Patients Treated for Localized Breast Cancer in the Adjuvant SettingNCT07859319 · 2027-01-01

NOT_YET_RECRUITING

Impact of Oncotype DX® on Treatment Recommendation and Its Economic Evaluation Under the Brazilian Society PerspectiveNCT05100277 · 2018-08-08

COMPLETED

Common interventions

CostOTHER1 Guideline Directed Intervention (GDI)OTHER1 Oncotype DX® AssayGENETIC1 Patient Experience QuestionnaireOTHER1 Phytotherapy Dietary Supplement (Harpagophytum, Meadowsweet, and Blackcurrant)DIETARY_SUPPLEMENT1 SwitchDRUG1

Leading sponsors

Dartmouth-Hitchcock Medical Center1 Hospices Civils de Lyon1 Hospital Perola Byington1

Trial status mix

COMPLETED1

NOT_YET_RECRUITING1

RECRUITING1

Phase mix

PHASE21

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.